Press Releases

12 October 2021

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Read more
16 September 2021

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Read more
21 July 2021

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Read more
WordPress Cookie Plugin by Real Cookie Banner